My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.51 -0.51 (-1.16%)

Delayed Quote Updated: 12:19 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed ↗

February 26, 2024

On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ:

Via Benzinga

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗

February 26, 2024

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Via InvestorPlace

Recap: Veracyte Q4 Earnings ↗

February 22, 2024

Via Benzinga

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

February 22, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

February 21, 2024

From Veracyte, Inc.

Via Business Wire

Earnings Outlook For Veracyte ↗

February 21, 2024

Via Benzinga

Veracyte: Q3 Earnings Insights ↗

November 07, 2023

Via Benzinga

Earnings Scheduled For February 22, 2024 ↗

February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.

Via Benzinga

The Latest Analyst Ratings for Veracyte ↗

October 20, 2023

Via Benzinga

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

February 08, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Completes Acquisition of C2i Genomics

February 06, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

January 08, 2024

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares ↗

December 27, 2023

On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO).

Via Benzinga

Topics ETFs

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 12, 2023

From Veracyte, Inc.

Via Business Wire

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

December 01, 2023

From Veracyte, Inc.

Via Business Wire

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

November 29, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

November 22, 2023

From Veracyte, Inc.

Via Business Wire

Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗

November 20, 2023

ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.

Via Talk Markets

Topics ETFs

Veracyte Announces Third Quarter 2023 Financial Results

November 07, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

November 07, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Stephens Annual Investment Conference

November 02, 2023

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

October 27, 2023

From Veracyte, Inc.

Via Business Wire

7 Undervalued Stocks That Analysts Love Right Now ↗

October 26, 2023

With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal.

Via InvestorPlace

Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023

October 17, 2023

From Veracyte, Inc.

Via Business Wire

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

October 12, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Stock Is Volatile After-Hours - Here's Why ↗

October 04, 2023

Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier...

Via Benzinga

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

October 04, 2023

From Veracyte, Inc.

Via Business Wire

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

September 28, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

September 28, 2023

From Veracyte, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.